Meta Information

ID:ertugliflozin

Name:Ertugliflozin

Schema Version:1.5

Alternate Names

• Steglatro

Intervention Type

therapeutic_agent

Expected Cost Mean

Low Cost:

150

High Cost:

550

Cost Type:

monthly

Description:

Prescription drug; cost varies widely with insurance coverage and generic availability.

Summary

Ertugliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It works by blocking the reabsorption of glucose in the kidneys, causing excess glucose to be excreted in the urine. This mechanism not only lowers blood sugar but also induces a mild, persistent ketogenic state, which may activate longevity pathways like AMPK, mimicking some metabolic benefits of caloric restriction.

Purpose

SGLT2 inhibitor that lowers blood glucose and mimics fasting.

Card Summary

An SGLT2 inhibitor that lowers blood glucose by promoting its excretion in urine, potentially mimicking some metabolic benefits of fasting for longevity.

Drug Class

sglt2-inhibitors

Drugs In Class

Empty Array

Impact

Score:

7

Justification:

Strong evidence for cardio-renal benefits, mimicking some aspects of caloric restriction.

Evidence

Grade:

A

Score:

9

Justification:

Multiple large-scale human RCTs confirm significant cardiovascular and renal protective effects.

Safety

Score:

5.5

Justification:

Regulated drug with common side effects (UTIs) and rare but serious risks.

Flags

• Increased risk of genital mycotic infections (yeast infections) and urinary tract infections.
• Carries a risk of euglycemic ketoacidosis, a serious metabolic state requiring immediate medical attention.
• May cause dehydration and hypotension (low blood pressure), especially in older adults or those on diuretics.
• A rare but severe risk of Fournier's gangrene (necrotizing fasciitis of the perineum) is associated with SGLT2 inhibitors.
• Contraindicated for individuals with severe kidney impairment (low eGFR).

Verdict

A promising metabolic modulator with strong evidence, but requires medical supervision.

Created

2026-04-27T00:50:16.280703Z

Model

Gemini 3.1 Pro (High)

Delivery

Route:

oral

Scope:

• systemic

Indication

Focus:

disease_treatment

Description:

Ertugliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It works by blocking the reabsorption of glucose in the kidneys, causing excess glucose to be excreted in the urine. This mechanism...

Typical Protocol

• A typical off-label protocol involves taking the lowest effective dose, 5 mg, once daily in the morning.